-+ 0.00%
-+ 0.00%
-+ 0.00%

IMMATICS demonstrated the clinical activity of IMA402 PRAME bispecific therapy and IMA203CD8 PRAME cell therapy in advanced solid tumors through two oral presentations at the 2026 ESMO annual meeting.

智通財經·10/24/2026 06:33:01
語音播報
IMMATICS demonstrated the clinical activity of IMA402 PRAME bispecific therapy and IMA203CD8 PRAME cell therapy in advanced solid tumors through two oral presentations at the 2026 ESMO annual meeting.